#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chorioretinitis Neurotrophic keratopathy Ovarian cancer stage III Malignant fibrous histiocytoma Transient ischaemic attack Ichthyosis Oesophageal squamous cell carcinoma stage II PIK3CA-activated mutation HER2 gene amplification Adenocarcinoma gastric Rhabdomyosarcoma recurrent Facioscapulohumeral muscular dystrophy Hyperinsulinaemic hypoglycaemia Squamous cell carcinoma of the cervix Central nervous system lymphoma More trials…

    Learn about Rare Diseases

    Factor VIII deficiency – Life with Disease Tuberous sclerosis complex – Trials in Disease Hereditary optic atrophy – Trials in Disease Erdheim-Chester disease Splenic marginal zone lymphoma – Basic Information Ewing’s sarcoma Nodal marginal zone B-cell lymphoma – Life with Disease Skin angiosarcoma – Diagnostics Skin angiosarcoma – Trials in Disease Advanced systemic mastocytosis More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Candesartan Cilexetil Linerixibat Tipranavir Ds-2325A Izaflortaucipir (18F) VORMATRIGINE Kan-101 Bemnifosbuvir Hemisulfate Losartan Temocillin Sodium Setrusumab Tolinapant Lactate Tisagenlecleucel Bi 764532 ULVIPRUBART Cyanocobalamin Pbf-999 Jnj-81241459 Tanimilast Iptacopan More therapies…

    Learn about Your Condition

    Partial lipodystrophy Retinitis pigmentosa Thyroidectomy Renal injury Status epilepticus Sickle cell anaemia Juvenile psoriatic arthritis Large cell lung cancer Benign neoplasm of ureter Osteonecrosis of jaw Genital infection female Drug dependence Desmoid tumour Exfoliation glaucoma Multiple sclerosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Nervous System Diseases

  • Study on the Effects of Siponimod on Imaging and Immune Markers in Patients with Progressive Multiple Sclerosis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Progressive multiple sclerosis
    Investigated Drugs:
    • Siponimod
    • Siponimod Fumaric Acid
    Italy

  • Study on Botulinum Toxin Type A and Sodium Chloride for Patients with Treatment-Resistant Chronic Cluster Headache

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cluster headache
    Investigated Drugs:
    • Botulinum Toxin Type A
    • Sodium Chloride
    Germany Norway

  • Study on Alzheimer’s Disease Using Flortaucipir (18F) for Early Diagnosis in At-Risk Patients

    Recruiting

    2 1 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Flortaucipir (18F)
    France

  • Study on Stereotactic Cisternal Lavage Therapy for Patients with Aneurysmal Subarachnoid Hemorrhage Using Urokinase, Nimodipine, and a Drug Combination

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Nimodipine
    • Urokinase
    • Sodium Chloride
    Germany

  • Study on the Effects of Ozanimod on Inflammation in Patients with Relapsing Multiple Sclerosis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Progressive relapsing multiple sclerosis
    • Relapsing-remitting multiple sclerosis
    • Multiple sclerosis
    Investigated Drugs:
    • Ozanimod
    Italy

  • Study on the Safety of VO659 for Patients with Spinocerebellar Ataxia Types 1, 3, and Huntington’s Disease

    Recruiting

    2 1 1
    Investigated Diseases:
    • Hereditary ataxia
    • Huntington’s disease
    Investigated Drugs:
    • Vo659
    Denmark France Germany The Netherlands
Previous Page
1 … 36 37 38 39 40 … 141
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!